PERIPHERAL ARTERIAL DISEASE AND CHRONIC KIDNEY DISEASE

Marijan Bosevski

University Cardiology Clinic, University of Ss. Cyril and Methodius, Skopje, Republic of Macedonia

Corresponding author: Marijan Bosevski, University Cardiology Clinic, University of Ss. Cyril and Methodius, Skopje, Republic of Macedonia, email: marijanbosevski@yahoo.com

ABSTRACT

There are two points of interplay of chronic kidney (CKD) and peripheral arterial disease (PAD): CKD has been recognized as one of the main factors for presence of PAD, and PAD has been defined as a useful tool for risk stratification of CKD population. Peripheral arterial disease in patients with CKD is a frequent finding, even in those without symptoms. This review tends to describe determinants for occurrence of arterial disease in chronic kidney disease patients and necessity for its screening.

Key words: peripheral arterial disease, chronic kidney disease, screening, risk factors, prognosis

INTRODUCTION

Cardiovascular disease (CVD) has been found in many studies as a high prevalent in patients with chronic kidney disease (CKD). Despite many studies dealing with coronary artery disease in CKD, there aren’t too many indicating the intersection of the peripheral arterial disease (PAD) and CKD. Coexistent PAD and renal artery disease are not uncommon. PAD as part of the CVD is found in 26-32% of the patients with CKD. The results from the National Health and Nutrition Examination Survey (NHANES) survey of PAD indicate that 24% of the persons with creatinine clearance <60 mL/min/1.73 m2 have PAD compared with 3.7% of the persons with creatinine clearance >60 mL/min/1.73 m2 [1]. ARIC studies and Heart and Estrogen/Progestin Replacement Study (HERS) revealed CKD as an independent risk factor for PAD with hazard ratio 1.1-3. Over 50% with end stage renal disease (ESRD) have some kind of vascular disease. The presence of PAD could additionally worsen the renal function in CKD patients [2,3].

CKD is linked with more extensive vascular disease than in the general population. There is a poor survival in those patients when both diseases are presented. The explanation is due to the mortality based on the coronary and cerebrovascular events in the patients with PAD (Figure 1) [4]. Additional facts are the high prevalence of the non-traumatic limb amputations in CKD, which is twice to three times higher than in the general population [5].

Figure 1. Survival of PAD patients with presented CKD
RISK FACTORS

Patients with PAD and CVD share the same traditional risk factors: age, diabetes, hypertension, hyperlipidemia, and smoking. However, the presence of PAD in CKD is associated with some unique risk factors, as: albuminuria, reduced GFR, inflammation, oxidative stress, endothelial dysfunction and abnormal metabolism of calcium and phosphate [6].

4D trial showed that patients with hyperlipidemia including with CKD have cumulative hazard from cardiac events twice to three times more if the target lipid levels are not reached. Diabetes and Hypertension are risk factors for all-cause death with the presence of heart failure in patients with CKD. Global Kidney Forum highlights the prevention of cardiovascular risk factors in CKD pts [7]. Every recommendation includes therapy goals for blood pressure treatment, lipid and glycemic control. The systematic review of randomized trials revealed that patients with CKD or diabetes and hypertension benefit much more with target blood pressure goal <130/80 mmHg than <140/80 mmHg. LDL should be the primary target for lipid control with value of 1.8 mmol (or 50% reduction from the initial value in very high risk patients), and 2.6 mmol/l in high risk patients. According to the ESC Guidelines 2016 every CKD with GFR 30-59 ml/min/1.73 m² or PAD is a high risk patient. Very high risk patient is the one with GFR <30 ml/min/173 m² or CKD with history or documentation of PAD or coronary artery disease [8].

These unique risk factors are involved in the depicted mechanisms of vascular calcification in chronic kidney disease, as a particular atherosclerotic process in these patients [9]. This is the reason some authors revealed CKD as a risk factor for vascular disease.

It has been recognized that phosphate had vascular toxicity and role in formation of vascular calcification [10]. Impaired endothelial function is an early phase of atherosclerotic disease and could be used for stratification of risk of vascular disease pts [11].

On the other hand, albuminuria in the general population, together with traditional risk factors predicts the risk of cardiovascular morbidity and all-cause mortality. Some authorities propose GFR to be added to the Framingham risk score because of independent role in cardiovascular prognosis in CKD and population with risk factors [12,13].

Our data revealed that inflammation in addition to other risk factors is in relation to carotid intima media thickness in this population, and in cardiovascular mortality, as well [14,15]. European and American guidelines recommend testing of CKD patients for detection of anemia and ferritin level as risk factors for heart failure and cardiovascular mortality [16].

SCREENING FOR PERIPHERAL ARTERIAL DISEASE

Table 1. Risk factors for PAD and CVD in general population and CKD

<table>
<thead>
<tr>
<th>Traditional</th>
<th>Non traditional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Albuminuria</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Reduced GFR</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Inflammation</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>Oxidative stress</td>
</tr>
<tr>
<td>Smoking</td>
<td>Endothelial dysfunction</td>
</tr>
<tr>
<td>Physical inactivity / Obesity</td>
<td>Anemia / malnutrition</td>
</tr>
</tbody>
</table>

Most of the published data support detection of PAD in CKD pts. A recent study showed that low ABI is predictor of organ failure, secondary end points and death [17]. This study made on 819 patients show prevalence of 46% of PAB in CKD. DOOPS and the Chronic Renal Insufficiency Cohort (CRIC) Studies’ results show necessities for screening of PAD because of high prevalence found in CKD population [18]. Own study done in the Department of Nephrology Skopje with collaboration of Cardiology showed frequent presence of PAD (over 50%) when done on population with CKD on hemodyalis. This study also shows high prevalence of carotid plaques (88%) in patients with low ABI and support screening for PAD in CKD [19].

The US Preventive Services Task Force recommendations on screening for PAD do not recommend it. Most of the societies and guidelines give recommendations for screening of PAD (Table 2) [20-22].

European Society for cardiology recommend vascular imaging in high risk patients (CKD included) as a risk modifier with class IIA or B [8]. The American Societies used PAD as a useful tool for risk stratification of CKD pts The cardiovascular risk scores (FRS-CVD and ASCVD [AHA/ACC 2013]) can estimate the probability of atherosclerotic cardiovascular events in patients with CKD regardless their renal function.

Some of the explanations why PAD is so important are that it is an advanced atherosclerotic...
disease with cumulative effect from many risk factors. Because PAD is a systemic manifestation of atherosclerosis it defines high risk patients per se.

Due to our experience we also recommend for PADs screening in CKD pts, also. Early detection may improve patient and clinician awareness of the potential significance of future leg symptoms or signs of more advanced PAD. This could lead to more intensive risk-factor intervention or initiation of medical therapies to improve limb symptoms and overall cardiovascular morbidity.

The most simple and used tool is the Ankle-Brachial Index (ABI). Its relation to traditional risk factors and renal function in high risk patients, was presented previously [23]. It is sensitive and accurate tool that provides diagnostic information with value ≤0.90, or >1.3. Contrast-based angiographic tests: computed tomography and magnetic resonance angiography are important tools in PAD diagnosis. However, advanced CKD patients have the highest risk of iodinated contrast–induced nephrotoxicity. That’s why they could be replaced with non-invasive imaging ultrasound techniques (echo color Doppler) in CKD population.

**CONCLUSION**

PAD is underdiagnosed and undertreated disease defined as a risk factor for CKD patients. CKD has been recognized as one of the main factors for prognosis of PAD, and PAD has been defined as a useful tool for risk stratification of CKD population.

The strategy for screening for PAD in CKD patients should be realized by multidisciplinary approach of nephrologists and cardiologist, in the way to improve clinical outcomes of this population.

**REFERENCES**

5. Eggers PW, Godhes D, Pugh J. Nontraumatic extremity amputations in the Medicare end-


